Skip to main content
CRIS
NASDAQ Life Sciences

Curis Inc. Receives Nasdaq Delisting Notice, Plans Appeal to Avoid Suspension

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$0.588
Mkt Cap
$23.667M
52W Low
$0.49
52W High
$3.13
Market data snapshot near publication time

summarizeSummary

Curis Inc. has officially received a delisting determination letter from Nasdaq due to its common stock failing to meet the minimum $1.00 bid price requirement, with trading suspension set for May 6, 2026, pending an appeal.


check_boxKey Events

  • Official Delisting Notice Received

    Curis Inc. received a Delist Determination Letter from Nasdaq on April 27, 2026, due to its common stock closing below the minimum $1.00 bid price for 30 consecutive business days.

  • Trading Suspension Imminent

    The company's securities are scheduled for delisting from the Nasdaq Capital Market and suspension of trading at the opening on May 6, 2026.

  • Company Plans to Appeal

    Curis Inc. intends to make a timely request for a new hearing with the Nasdaq Hearings Panel, which will stay further delisting actions, though success is not assured.

  • Prior Monitoring Accelerated Delisting

    This delisting follows a period under a Discretionary Panel Monitor, which precluded the company from receiving a compliance plan or additional time to regain compliance.


auto_awesomeAnalysis

This 8-K confirms the formal delisting notice from Nasdaq, a critical development for Curis Inc. The company's stock has consistently traded below the $1.00 minimum bid price, triggering the delisting process. This event follows a prior disclosure where the company was placed under a Discretionary Panel Monitor, indicating a heightened risk of delisting for any further non-compliance. While the company intends to appeal, there is no guarantee of success, which could lead to a significant loss of liquidity and investor confidence. This further compounds the "going concern" doubts previously disclosed in their 10-K, signaling severe operational and financial challenges.

At the time of this filing, CRIS was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.7M. The 52-week trading range was $0.49 to $3.13. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CRIS - Latest Insights

CRIS
May 01, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
9
CRIS
May 01, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
CRIS
Apr 21, 2026, 4:52 PM EDT
Filing Type: DEF 14A
Importance Score:
9
CRIS
Apr 10, 2026, 4:19 PM EDT
Filing Type: PRE 14A
Importance Score:
9
CRIS
Mar 24, 2026, 5:05 PM EDT
Source: Wiseek News
Importance Score:
9
CRIS
Mar 24, 2026, 5:00 PM EDT
Filing Type: 10-K
Importance Score:
9
CRIS
Mar 19, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
9
CRIS
Mar 17, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
CRIS
Feb 19, 2026, 4:12 PM EST
Filing Type: DEF 14A
Importance Score:
9
CRIS
Feb 13, 2026, 4:21 PM EST
Filing Type: S-3
Importance Score:
9